Azora Therapeutics Appoints Habtezion, Hastings and Soloway to Board

• Azora Therapeutics appointed Aida Habtezion, Paul Hastings and Thomas Soloway to its board on November 3, 2026.
• Habtezion, formerly Pfizer's chief medical officer, has a board term expiring at the 2028 annual meeting.
• Hastings, Nkarta's CEO, chairs the nominating and corporate governance committee; his board term expires at the 2029 annual meeting.
• Soloway, T-knife Therapeutics' CEO, chairs the audit committee; his board term expires at the 2029 annual meeting.
• Wendy Young chairs the compensation committee, joined by Soloway and Habtezion; Young and Hastings also joined the audit committee.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azora Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-117201), on November 09, 2026, and is solely responsible for the information contained therein.